Trial · NCT05432518
Pilot Trial for Treatment of Recurrent Glioblastoma
NCT05432518, Early phase 1, Enrolling by invitation, AHS Cancer Control Alberta
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Trial for Treatment of Recurrent Glioblastoma. Trials, record NCT05432518. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05432518
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Trial for Treatment of Recurrent Glioblastoma
- NCT number
- NCT05432518
- Status
- Enrolling by invitation
- Phases
- Early phase 1
- Enrollment
- 10 participants, estimated
- Lead sponsor
- AHS Cancer Control Alberta
- Conditions
- Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
- Interventions
- Afatinib, Dasatinib, Palbociclib, Everolimus, Olaparib
- First posted
- 2022-06-27
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Success rate of personalized GBM treatment based on molecular characterization of recurrent tumor | From date of initial consent to participate to the end of follow up period (24 months) | Percentage of patients, interested in participating, consented and detected with target mutations and completed the treatment with one of the 5 study drugs |
| Secondary | Overall survival (OS) | From date of study drug administration until date of death from any cause (approximately 24 months) | OS is calculated as the period from the day of starting administration of the study drug to the day of death from any cause. |
| Secondary | Progression free survival (PFS) | From date of study drug administration until date of radiographic confirmed progression (approximately 2 years) | PFS is calculated as the period from the day of starting administration of the study drug to the date that disease progression is confirmed by radiographic assessment and RANO criteria. |
| Secondary | Quality of Life (QoL) EORTC QLQ-C30 | Baseline until the end of treatment | The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented. |
| Secondary | Quality of Life (QoL) EORTC QLQ BN-20 | Baseline until the end of treatment | Quality of Life measures are recorded according to EORTC QLQ BN-20 module, which is validated for brain tumor patients and measured as a unit of scale. This is a standard tool for assessing patient reported quality of Life along time during treatment. EORTC QLQ BN-20 (BN-20): 4 scales comprised of multiple items and 7 single items. All items are rated on a 4-point Likert-type scale, 1=not at all' to 4=very much, and linearly transformed to a 0-100 scale, higher scores indicating more severe symptoms. The scores across all time points were averaged to obtain the mean. |
| Other | Genomic and expression profiling | From date of initial consent to participate to end of follow up period (24 months) | Number of patients for whom we were able to have genomic and expression profiling on their tissue samples and organoids |
| Other | Organoid drug response | From date of initial consent to participate to end of follow up period (24 months) | Number of patients for whom we can determine organoid drug response to study drugs |
| Other | Correlation of genomic and expression profiling of tissue and organoid with the organoid's best drug response | From date of initial consent to participate to end of follow up period (24 months) | Number of patients for whom the genomic and expression profiling of their tissue and organoid directly correlates to the organoid's best drug response |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05432518
GET https://conductscience.org/api/trials/v1/NCT05432518/registered